Treatment of pulmonary hypertension with left heart disease: a concise review

References

• GalièNHumbertMVachieryJL2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)Eur Heart J20163716711926320113
   PubMed Web of Science ®Google Scholar
• HoeperMMBogaardHJCondliffeRDefinitions and diagnosis of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD42D5024355641
   PubMed Web of Science ®Google Scholar
• SimonneauGGatzoulisMAAdatiaIUpdated clinical classification of pulmonary hypertensionJ Am Coll Cardiol20136225 SupplD34D4124355639
   PubMed Web of Science ®Google Scholar
• KovacsGAvianAPiennMNaeijeROlschewskiHReading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swingsAm J Respir Crit Care Med2014190325225724869464
   PubMed Web of Science ®Google Scholar
• HuntSAAbrahamWTChinMHAmerican College of Cardiology FoundationAmerican Heart Association2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung TransplantationJ Am Coll Cardiol20095315e1e9019358937
   PubMed Web of Science ®Google Scholar
• Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC)European Respiratory Society (ERS)International Society of Heart and Lung Transplantation (ISHLT)GalièNHoeperMMHumbertMGuidelines for diagnosis and treatment of pulmonary hypertensionEur Respir J20093461219126319749199
   PubMed Web of Science ®Google Scholar
• VachiéryJLAdirYBarberàJAPulmonary hypertension due to left heart diseasesJ Am Coll Cardiol20136225 SupplD100D10824355634
   PubMed Web of Science ®Google Scholar
• RosenkranzSGibbsJSWachterRDe MarcoTVonk-NoordegraafAVachiéryJLLeft ventricular heart failure and pulmonary hypertensionEur Heart J2016371294295426508169
   PubMed Web of Science ®Google Scholar
• GuazziMBorlaugBAPulmonary hypertension due to left heart diseaseCirculation2012126897599022908015
   PubMed Web of Science ®Google Scholar
• MelenovskyVHwangSJLinGRedfieldMMBorlaugBARight heart dysfunction in heart failure with preserved ejection fractionEur Heart J201435483452346224875795
   PubMed Web of Science ®Google Scholar
• MohammedSFHussainIAbouEzzeddineOFRight ventricular function in heart failure with preserved ejection fraction: a community-based studyCirculation2014130252310232025391518
   PubMed Web of Science ®Google Scholar
• BursiFMcNallanSMRedfieldMMPulmonary pressures and death in heart failure: a community studyJ Am Coll Cardiol201259322223122240126
   PubMed Web of Science ®Google Scholar
• DamyTGoodeKMKallvikbacka-BennettADeterminants and prognostic value of pulmonary arterial pressure in patients with chronic heart failureEur Heart J201031182280229020693169
   PubMed Web of Science ®Google Scholar
• GergesCGergesMLangMBDiastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertensionChest2013143375876623580984
   PubMed Web of Science ®Google Scholar
• NaeijeRVachieryJLYerlyPVanderpoolRThe transpulmonary pressure gradient for the diagnosis of pulmonary vascular diseaseEur Respir J201341121722322936712
   PubMed Web of Science ®Google Scholar
• BorlaugBANishimuraRASorajjaPLamCSRedfieldMMExercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fractionCirc Heart Fail20103558859520543134
   PubMed Web of Science ®Google Scholar
• McLaughlinVVShahSJSouzaRHumbertMManagement of pulmonary arterial hypertensionJ Am Coll Cardiol201565181976199725953750
   PubMed Web of Science ®Google Scholar
• HagerWDCollinsITateJPExercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patientsClin Respir J20137322723622789029
   PubMed Web of Science ®Google Scholar
• RobbinsIMHemnesARPughMEHigh prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertensionCirc Heart Fail20147111612224297689
   PubMed Web of Science ®Google Scholar
• FoxBDShimonyALanglebenDHigh prevalence of occult left heart disease in scleroderma-pulmonary hypertensionEur Respir J20134241083109123258775
   PubMed Web of Science ®Google Scholar
• CaliffRMAdamsKFMcKennaWJA randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)Am Heart J1997134144549266782
   PubMed Web of Science ®Google Scholar
• LüscherTFEnseleitFPacherRHeart Failure ET(A) Receptor Blockade TrialHemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)Circulation2002106212666267212438291
   PubMed Web of Science ®Google Scholar
• KalraPRMoonJCCoatsAJDo results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?Int J Cardiol2002852–319519712208583
   PubMed Web of Science ®Google Scholar
• AnandIMcMurrayJCohnJNEARTH investigatorsLong-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialLancet2004364943134735415276394
   PubMed Web of Science ®Google Scholar
• PackerMMcMurrayJMassieBMClinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyJ Card Fail2005111122015704058
   PubMed Web of Science ®Google Scholar
• KaluskiECotterGLeitmanMClinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multi-center randomized studyCardiology2008109427328017873492
   PubMed Web of Science ®Google Scholar
• LewisGDShahRShahzadKSildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertensionCirculation2007116141555156217785618
   PubMed Web of Science ®Google Scholar
• BehlingARohdeLEColomboFCGoldraichLASteinRClausellNEffects of 5’-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trialJ Card Fail200814318919718381181
   PubMed Web of Science ®Google Scholar
• GuazziMVicenziMArenaRGuazziMDPulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodies-terase-5 inhibition in a 1-year studyCirculation2011124216417421709061
   PubMed Web of Science ®Google Scholar
• GuazziMVicenziMArenaRPhosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled studyEur J Heart Fail2012141829022067410
   PubMed Web of Science ®Google Scholar
• RedfieldMMChenHHBorlaugBARELAX TrialEffect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trialJAMA2013309121268127723478662
   PubMed Web of Science ®Google Scholar
• HoendermisESLiuLCHummelYMEffects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trialEur Heart J201536382565257326188003
   PubMed Web of Science ®Google Scholar
• ForfiaPRBorlaugBALetter by Forfia and Borlaug regarding article, “Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study”Circulation20121258e408 author reply e409–e41022371450
   PubMed Web of Science ®Google Scholar
• WuXYangTZhouQLiSHuangLAdditional use of a phosphodi-esterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysisEur J Heart Fail201416444445324464734
   PubMed Web of Science ®Google Scholar
• BondermanDGhioSFelixSBLeft Ventricular Systolic Dysfunction Associated with Pulmonary Hypertension Riociguat Trial (LEPHT) Study GroupRiociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic studyCirculation2013128550251123775260
   PubMed Web of Science ®Google Scholar
• BondermanDPretschISteringer-MascherbauerRAcute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single dose studyChest201414651274128524991733
   PubMed Web of Science ®Google Scholar
• ReichenbergerFPepke-ZabaJMcNeilKParameshwarJShapiroLMAtrial septostomy in the treatment of severe pulmonary arterial hypertensionThorax200358979780012947142
   PubMed Web of Science ®Google Scholar
• KurzynaMDabrowskiMBieleckiDAtrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertensionChest2007131497798317426198
   PubMed Web of Science ®Google Scholar
• HoeperMMMcLaughlinVVDalaanAMSatohTGalièNTreatment of pulmonary hypertensionLancet Respir Med20164432333626975811
   PubMed Web of Science ®Google Scholar